Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)’s shares have lost ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

This funding will allow LiFT to take its immuno-modulatory alpha neutrophil (IMAN)-based therapy to Phase I clinical trials ...

Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.